Ruham Alshiekh Nasany
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruham Alshiekh Nasany has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Dipak K. Dube
Department of Medicine SUNY Upstate Medical University Syracuse New York USA
4 shared publications Lynn Abbott
Department of Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA
4 shared publicationsBernard J. Poiesz
Department of Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA
3 shared publicationsSyamalima Dube
Department of Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA
3 shared publications- Amr Matoq
Nemours Cardiac Center, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA
2 shared publications - Eli Louis Diamond
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200495
Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy
Histiocytoses are diverse hematopoietic diseases with disabling neurologic involvement. Recently, targeted mitogen-activated protein kinase pathway inhibitors have been used with clinical and radiologic response; however, some patients are unable to tolerate these treatments or have isolated and/or refractory neurologic, ocular, or head and neck (NOHN) disease. Intra-arterial administration of chemotherapy has conferred favorable responses in various neoplasms; however, treatment and outcomes across histiocytosis subtypes have not been examined. Patients with biopsy-proven histiocytosis involving NOHN structures underwent an outpatient interventional procedure with angiography, selective catheterization, and intra-arterial infusion of melphalan, with target arteries depending on the site of disease. Patients were followed with radiologic (i.e., PET/CT, CT, MRI, or ophthalmic ultrasound and optical coherence tomography) and quantified functional assessments (i.e., vision, speech, or balance) as appropriate. Complete or partial radiologic and functional response rates were captured as well as frequency of subsequent progression. Eighteen patients underwent 74 total treatment instances. For 14 patients with radiologically evaluable tumorous disease, 10 (71%) had partial or complete response and the remaining 4 had stable disease; 3 of 14 (21%) had subsequent radiologic progression. Of 13 functionally evaluable patients, including 6 with neurodegenerative histiocytosis, 12 (92%) experienced functional improvement; 7 of 13 (54%) had subsequent functional worsening consistent with disease progression. There were no intraprocedural complications; 3 patients required hospitalization following treatment, including 1 patient with allergic reaction to melphalan. For patients with tumorous and neurodegenerative histiocytosis, intra-arterial melphalan represents a safe and highly effective treatment with potential to improve neurologic function. Additional study may clarify patients most suitable for this intervention. This novel treatment modality may represent a practice-changing innovation for refractory histiocytosis involving neurologic and ocular structures, as well as neurodegenerative forms. The treatment delivery form is novel, and future work should be directed at studying the efficacy of this modality to other forms of neurologic, ocular, head, and neck cancers. This study provides Class IV evidence that in patients with tumorous or neurodegenerative histiocytosis, selective angiographic catheterization and intra-arterial infusion of melphalan result in radiologic and functional improvement.
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200495
Open AccessRefractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy
Histiocytoses are diverse hematopoietic diseases with disabling neurologic involvement. Recently, targeted mitogen-activated protein kinase pathway inhibitors have been used with clinical and radiologic response; however, some patients are unable to tolerate these treatments or have isolated and/or refractory neurologic, ocular, or head and neck (NOHN) disease. Intra-arterial administration of chemotherapy has conferred favorable responses in various neoplasms; however, treatment and outcomes across histiocytosis subtypes have not been examined. Patients with biopsy-proven histiocytosis involving NOHN structures underwent an outpatient interventional procedure with angiography, selective catheterization, and intra-arterial infusion of melphalan, with target arteries depending on the site of disease. Patients were followed with radiologic (i.e., PET/CT, CT, MRI, or ophthalmic ultrasound and optical coherence tomography) and quantified functional assessments (i.e., vision, speech, or balance) as appropriate. Complete or partial radiologic and functional response rates were captured as well as frequency of subsequent progression. Eighteen patients underwent 74 total treatment instances. For 14 patients with radiologically evaluable tumorous disease, 10 (71%) had partial or complete response and the remaining 4 had stable disease; 3 of 14 (21%) had subsequent radiologic progression. Of 13 functionally evaluable patients, including 6 with neurodegenerative histiocytosis, 12 (92%) experienced functional improvement; 7 of 13 (54%) had subsequent functional worsening consistent with disease progression. There were no intraprocedural complications; 3 patients required hospitalization following treatment, including 1 patient with allergic reaction to melphalan. For patients with tumorous and neurodegenerative histiocytosis, intra-arterial melphalan represents a safe and highly effective treatment with potential to improve neurologic function. Additional study may clarify patients most suitable for this intervention. This novel treatment modality may represent a practice-changing innovation for refractory histiocytosis involving neurologic and ocular structures, as well as neurodegenerative forms. The treatment delivery form is novel, and future work should be directed at studying the efficacy of this modality to other forms of neurologic, ocular, head, and neck cancers. This study provides Class IV evidence that in patients with tumorous or neurodegenerative histiocytosis, selective angiographic catheterization and intra-arterial infusion of melphalan result in radiologic and functional improvement.
- Open Access
- 15 April 2023
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (5) , 225-233
Therapies for IDH-Mutant Gliomas
Purpose of Review: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct type of primary brain tumors with unique characteristics, behavior, and disease outcomes. This article provides a review of standard of care treatment options and innovative, therapeutic approaches that are currently under investigation for these tumors. Recent Findings: Extensive pre-clinical data and a variety of clinical studies support targeting IDH mutations in glioma using different mechanisms, which include direct inhibition and immunotherapies that target metabolic and epigenomic vulnerabilities caused by these mutations. Summary: IDH mutations have been recognized as an oncogenic driver in gliomas for more than a decade and as a positive prognostic factor influencing the research for new therapeutic methods including IDH inhibitors, DNA repair inhibitors, and immunotherapy.
- 15 April 2023
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (5) , 225-233
Open AccessTherapies for IDH-Mutant Gliomas
Purpose of Review: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct type of primary brain tumors with unique characteristics, behavior, and disease outcomes. This article provides a review of standard of care treatment options and innovative, therapeutic approaches that are currently under investigation for these tumors. Recent Findings: Extensive pre-clinical data and a variety of clinical studies support targeting IDH mutations in glioma using different mechanisms, which include direct inhibition and immunotherapies that target metabolic and epigenomic vulnerabilities caused by these mutations. Summary: IDH mutations have been recognized as an oncogenic driver in gliomas for more than a decade and as a positive prognostic factor influencing the research for new therapeutic methods including IDH inhibitors, DNA repair inhibitors, and immunotherapy.
- Open Access
- 8 June 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 96 (23) , 1091-1093
Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis
- 8 June 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 96 (23) , 1091-1093
Open AccessIntra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi222-vi223
RARE-08. ROSAI-DORFMAN-DESTOMBES DISEASE OF THE NERVOUS SYSTEM; A SYSTEMATIC LITERATURE REVIEW
INTRODUCTION: Rosai-Dorfman-Destombes disease (RDD) is a rare non–Langerhans cell histiocytosis with neurologic involvement in fewer than 5% of cases. Data about neurologic RDD is limited. Our objective was to synthesize the clinical literature about presentation, treatments, and outcomes of neurologic RDD. METHODS: A multi-database English systematic review search using keywords related to (1) histiocytosis and (2) neurologic involvement. Candidate articles were screened for clinical content. Secondary literature and cases without treatment information were excluded. Sites of involvement, presenting symptoms, treatments, and therapeutic responses were reviewed. RESULTS: Of 4768 screened, 153 articles presenting 223 patients were included. Mean age was 37.7 years (range 2–79; IQR 23.5–52.5). 149 patients (66.8%) were male and 74 (33.2%) were female. RDD lesions were located in the dura in 111 (49.8%) of cases, spine in 16.6%, brain parenchyma in 9.0%, orbit in 7.2%, calvarium in 2.7%, and in multiple sites in 13.5%. The most frequent presenting symptoms were headache in 101 (45.3%.), focal neurological deficits (32.7%), visual symptoms (31.8%), seizures (24.7%), cranial (11.7%), and cerebellar dysfunction (11.2%). Cognitive decline, masses were less common presentations. First-line treatments included resection, radiation, corticosteroids, chemotherapy, and combinations of these. First-line treatment led to complete (CR) or partial response (PR) in 153 (68.6%) of cases, stable disease in 30 (13.5%), and progressive disease in 40 (17.9%). CR or PR was observed in the calvarium in 5/6 (83.3%), dura in 82/111 (73.9%), spine in 29/37 (78.4%), orbit 8/16 (50.0%), parenchyma in 15/20 (75.0%), and multiple sites in 14/30 (46.7%). 47 (21.1%) of patients required second-line therapy. DISCUSSION: Neurologic RDD is a rare form of histiocytosis with varying sites of involvement, clinical presentations, and responses to treatment. Further investigation of effective therapies for neurologic RDD may improve outcomes for this disease.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi222-vi223
RARE-08. ROSAI-DORFMAN-DESTOMBES DISEASE OF THE NERVOUS SYSTEM; A SYSTEMATIC LITERATURE REVIEW
INTRODUCTION: Rosai-Dorfman-Destombes disease (RDD) is a rare non–Langerhans cell histiocytosis with neurologic involvement in fewer than 5% of cases. Data about neurologic RDD is limited. Our objective was to synthesize the clinical literature about presentation, treatments, and outcomes of neurologic RDD. METHODS: A multi-database English systematic review search using keywords related to (1) histiocytosis and (2) neurologic involvement. Candidate articles were screened for clinical content. Secondary literature and cases without treatment information were excluded. Sites of involvement, presenting symptoms, treatments, and therapeutic responses were reviewed. RESULTS: Of 4768 screened, 153 articles presenting 223 patients were included. Mean age was 37.7 years (range 2–79; IQR 23.5–52.5). 149 patients (66.8%) were male and 74 (33.2%) were female. RDD lesions were located in the dura in 111 (49.8%) of cases, spine in 16.6%, brain parenchyma in 9.0%, orbit in 7.2%, calvarium in 2.7%, and in multiple sites in 13.5%. The most frequent presenting symptoms were headache in 101 (45.3%.), focal neurological deficits (32.7%), visual symptoms (31.8%), seizures (24.7%), cranial (11.7%), and cerebellar dysfunction (11.2%). Cognitive decline, masses were less common presentations. First-line treatments included resection, radiation, corticosteroids, chemotherapy, and combinations of these. First-line treatment led to complete (CR) or partial response (PR) in 153 (68.6%) of cases, stable disease in 30 (13.5%), and progressive disease in 40 (17.9%). CR or PR was observed in the calvarium in 5/6 (83.3%), dura in 82/111 (73.9%), spine in 29/37 (78.4%), orbit 8/16 (50.0%), parenchyma in 15/20 (75.0%), and multiple sites in 14/30 (46.7%). 47 (21.1%) of patients required second-line therapy. DISCUSSION: Neurologic RDD is a rare form of histiocytosis with varying sites of involvement, clinical presentations, and responses to treatment. Further investigation of effective therapies for neurologic RDD may improve outcomes for this disease.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi233
RARE-52. AN EXTRA-VENTRICULAR NEUROCYTOMA PRESENTING WITH DIFFUSE LEPTOMENINGEAL DISEASE WITH OPTIC NEURITIS, A CASE REPORT
INTRODUCTION: Neurocytoma is classically a rare intraventricular tumor that affects young adults. Due to its location, it usually presents with obstructive hydrocephalus and typically has a favorable prognosis after adequate surgical intervention. CASE: In this report, we describe the case of a 19-year-old man who developed progressive decreased visual acuity and headaches that led to a diagnosed of hydrocephalus and a ventriculoperitoneal shunt (VPS) placement. Work up at presentation revealed a thoracic spinal cord tumor which was completed resected and pathology was consistent with extra-ventricular neurocytoma. With no further intervention, he experienced signs of worsening intracranial pressure (ICP) and visual acuity, becoming steroid-dependent. Repeat imaging 3 months later showed early signs of leptomeningeal disease (LMD), optic nerve enhancement, and diffuse dural thickening. A dural biopsy was done and read as nonspecific inflammation. He then came to our center for a second opinion. We reviewed pathology from original tumor and confirmed extra-ventricular neurocytoma. We, however, read the dural biopsy as an organizing subdural hematoma. We analyzed his cerebrospinal fluid (CSF) and cytology showed neurocytoma cells, linking his LMD to initial diagnosis. He went on to receive photon craniospinal radiation (CSI) with clinical improvement and decreased steroid requirements. Most recent imaging showed improving LMD. DISCUSSION: Extra-ventricular neurocytoma is an extremely rare disease with very few cases reported in the literature and our case is unique due to the severe leptomeningeal involvement affecting the optic nerves and the presence of neurocytoma cells on the CSF. There is no consensus on how to best treat these cases, however, our patient improved after CSI.
- 11 November 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (Supplement) , vi233
RARE-52. AN EXTRA-VENTRICULAR NEUROCYTOMA PRESENTING WITH DIFFUSE LEPTOMENINGEAL DISEASE WITH OPTIC NEURITIS, A CASE REPORT
INTRODUCTION: Neurocytoma is classically a rare intraventricular tumor that affects young adults. Due to its location, it usually presents with obstructive hydrocephalus and typically has a favorable prognosis after adequate surgical intervention. CASE: In this report, we describe the case of a 19-year-old man who developed progressive decreased visual acuity and headaches that led to a diagnosed of hydrocephalus and a ventriculoperitoneal shunt (VPS) placement. Work up at presentation revealed a thoracic spinal cord tumor which was completed resected and pathology was consistent with extra-ventricular neurocytoma. With no further intervention, he experienced signs of worsening intracranial pressure (ICP) and visual acuity, becoming steroid-dependent. Repeat imaging 3 months later showed early signs of leptomeningeal disease (LMD), optic nerve enhancement, and diffuse dural thickening. A dural biopsy was done and read as nonspecific inflammation. He then came to our center for a second opinion. We reviewed pathology from original tumor and confirmed extra-ventricular neurocytoma. We, however, read the dural biopsy as an organizing subdural hematoma. We analyzed his cerebrospinal fluid (CSF) and cytology showed neurocytoma cells, linking his LMD to initial diagnosis. He went on to receive photon craniospinal radiation (CSI) with clinical improvement and decreased steroid requirements. Most recent imaging showed improving LMD. DISCUSSION: Extra-ventricular neurocytoma is an extremely rare disease with very few cases reported in the literature and our case is unique due to the severe leptomeningeal involvement affecting the optic nerves and the presence of neurocytoma cells on the CSF. There is no consensus on how to best treat these cases, however, our patient improved after CSI.
- Open Access
- 19 April 2017
- Published by ScopeMed in Open Veterinary Journal
- Vol. 7 (2) , 180-191
Expression of various sarcomeric tropomyosin isoforms in equine striated muscles
Expression of various sarcomeric tropomyosin isoforms in equine striated muscles
- 19 April 2017
- Published by ScopeMed in Open Veterinary Journal
- Vol. 7 (2) , 180-191
Open AccessExpression of various sarcomeric tropomyosin isoforms in equine striated muscles
Expression of various sarcomeric tropomyosin isoforms in equine striated muscles
- 20 December 2016
- Published by Wiley in Cytoskeleton
- Vol. 74 (3) , 125-142
Identification, characterization, and expression of sarcomeric tropomyosin isoforms in zebrafish
Tropomyosin is a component of thin filaments that constitute myofibrils, the contractile apparatus of striated muscles. In vertebrates, except for fish, four TPM genes TPM1, TPM2, TPM3, and TPM4 are known. In zebrafish, there are six TPM genes that include the paralogs of the TPM1 (TPM1‐1 and TPM1‐2), the paralogs of the TPM4 gene (TPM4‐1 and TPM4‐2), and the two single copy genes TPM2 and TPM3. In this study, we have identified, cloned, and sequenced the TPM1‐1κ isoform of the TPM1‐1 gene and also discovered a new isoform TPM1‐2ν of the TPM1‐2. Further, we have cloned and sequenced the sarcomeric isoform of the TPM4‐2 gene designated as TPM4‐2α. Using conventional RT‐PCR, we have shown the expression of the sarcomeric isoforms of TPM1‐1, TPM1‐2, TPM2, TPM3, TPM4‐1, and TPM4‐2 in heart and skeletal muscles. By qRT‐PCR using both relative expression as well as the absolute copy number, we have shown that TPM1‐1α, TPM1‐2α, and TPM1‐2ν are expressed mostly in skeletal muscle; the level of expression of TPM1‐1κ is significantly lower compared to TPM1‐1α in skeletal muscle. In addition, both TPM4‐1α and TPM4‐2α are predominantly expressed in heart. 2D Western blot analyses using anti‐TPM antibody followed by Mass Spectrometry of the proteins from the antibody‐stained spots show that TPM1‐1α and TPM3α are expressed in skeletal muscle whereas TPM4‐1α and TPM3α are expressed in zebrafish heart. To the best of our knowledge, this is by far the most comprehensive analysis of tropomyosin expression in zebrafish, one of the most popular animal models for gene expression study.
- 20 December 2016
- Published by Wiley in Cytoskeleton
- Vol. 74 (3) , 125-142
Identification, characterization, and expression of sarcomeric tropomyosin isoforms in zebrafish
Tropomyosin is a component of thin filaments that constitute myofibrils, the contractile apparatus of striated muscles. In vertebrates, except for fish, four TPM genes TPM1, TPM2, TPM3, and TPM4 are known. In zebrafish, there are six TPM genes that include the paralogs of the TPM1 (TPM1‐1 and TPM1‐2), the paralogs of the TPM4 gene (TPM4‐1 and TPM4‐2), and the two single copy genes TPM2 and TPM3. In this study, we have identified, cloned, and sequenced the TPM1‐1κ isoform of the TPM1‐1 gene and also discovered a new isoform TPM1‐2ν of the TPM1‐2. Further, we have cloned and sequenced the sarcomeric isoform of the TPM4‐2 gene designated as TPM4‐2α. Using conventional RT‐PCR, we have shown the expression of the sarcomeric isoforms of TPM1‐1, TPM1‐2, TPM2, TPM3, TPM4‐1, and TPM4‐2 in heart and skeletal muscles. By qRT‐PCR using both relative expression as well as the absolute copy number, we have shown that TPM1‐1α, TPM1‐2α, and TPM1‐2ν are expressed mostly in skeletal muscle; the level of expression of TPM1‐1κ is significantly lower compared to TPM1‐1α in skeletal muscle. In addition, both TPM4‐1α and TPM4‐2α are predominantly expressed in heart. 2D Western blot analyses using anti‐TPM antibody followed by Mass Spectrometry of the proteins from the antibody‐stained spots show that TPM1‐1α and TPM3α are expressed in skeletal muscle whereas TPM4‐1α and TPM3α are expressed in zebrafish heart. To the best of our knowledge, this is by far the most comprehensive analysis of tropomyosin expression in zebrafish, one of the most popular animal models for gene expression study.
- Open Access
- 9 November 2016
- Published by Wiley in Clinical Case Reports
- Vol. 4 (12) , 1184-1186
Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
Key Clinical Message: New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.
- 9 November 2016
- Published by Wiley in Clinical Case Reports
- Vol. 4 (12) , 1184-1186
Open AccessExtensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
Key Clinical Message: New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.
- Open Access
- 15 September 2016
- Published by Wiley in Molecular Biology International
- Vol. 2016, 1-11
Cloning, Sequencing, and the Expression of the Elusive Sarcomeric TPM4αIsoform in Humans
In mammals, tropomyosin is encoded by four known TPM genes (TPM1, TPM2, TPM3, and TPM4) each of which can generate a number of TPM isoforms via alternative splicing and/or using alternate promoters. In humans, the sarcomeric isoform(s) of each of the TPM genes, except for the TPM4, have been known for a long time. Recently, on the basis of computational analyses of the human genome sequence, the predicted sequence of TPM4αhas been posted in GenBank. We designed primer-pairs for RT-PCR and showed the expression of the transcripts of TPM4αand a novel isoform TPM4δin human heart and skeletal muscle. qRT-PCR shows that the relative expression of TPM4αand TPM4δis higher in human cardiac muscle. Western blot analyses using CH1 monoclonal antibodies show the absence of the expression of TPM4δprotein (~28 kDa) in human heart muscle. 2D western blot analyses with the same antibody show the expression of at least nine distinct tropomyosin molecules with a mass ~32 kD and above in adult heart. By Mass spectrometry, we determined the amino acid sequences of the extracted proteins from these spots. Spot “G” reveals the putative expression of TPM4αalong with TPM1αprotein in human adult heart.
- 15 September 2016
- Published by Wiley in Molecular Biology International
- Vol. 2016, 1-11
Open AccessCloning, Sequencing, and the Expression of the Elusive Sarcomeric TPM4αIsoform in Humans
In mammals, tropomyosin is encoded by four known TPM genes (TPM1, TPM2, TPM3, and TPM4) each of which can generate a number of TPM isoforms via alternative splicing and/or using alternate promoters. In humans, the sarcomeric isoform(s) of each of the TPM genes, except for the TPM4, have been known for a long time. Recently, on the basis of computational analyses of the human genome sequence, the predicted sequence of TPM4αhas been posted in GenBank. We designed primer-pairs for RT-PCR and showed the expression of the transcripts of TPM4αand a novel isoform TPM4δin human heart and skeletal muscle. qRT-PCR shows that the relative expression of TPM4αand TPM4δis higher in human cardiac muscle. Western blot analyses using CH1 monoclonal antibodies show the absence of the expression of TPM4δprotein (~28 kDa) in human heart muscle. 2D western blot analyses with the same antibody show the expression of at least nine distinct tropomyosin molecules with a mass ~32 kD and above in adult heart. By Mass spectrometry, we determined the amino acid sequences of the extracted proteins from these spots. Spot “G” reveals the putative expression of TPM4αalong with TPM1αprotein in human adult heart.
- 4 February 2016
- Published by S. Karger AG in Acta Haematologica
- Vol. 135 (4) , 208-210
L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity
Introduction: Similar to pediatric regimens, multiple doses of L-asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults is high-grade hyperbilirubinemia and transaminitis. Despite being almost always reversible and may not recur, clinicians may still be reluctant to continue with PEG-Asp in patients with liver toxicity, losing the benefit from multiple doses of the drug. Case Report: We describe a case of adult ALL who developed PEG-Asp-related high grade liver toxicity. The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine. This case goes in line with similar observations in animal models and humans. Conclusion:L-Carnitine may show therapeutic benefit in PEG-Asp-related hepatotoxicity and should be considered in clinical trials of the drug.
- 4 February 2016
- Published by S. Karger AG in Acta Haematologica
- Vol. 135 (4) , 208-210
L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity
Introduction: Similar to pediatric regimens, multiple doses of L-asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults is high-grade hyperbilirubinemia and transaminitis. Despite being almost always reversible and may not recur, clinicians may still be reluctant to continue with PEG-Asp in patients with liver toxicity, losing the benefit from multiple doses of the drug. Case Report: We describe a case of adult ALL who developed PEG-Asp-related high grade liver toxicity. The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine. This case goes in line with similar observations in animal models and humans. Conclusion:L-Carnitine may show therapeutic benefit in PEG-Asp-related hepatotoxicity and should be considered in clinical trials of the drug.